Granules

Drugmaker Granules India on Thursday warned of a significant loss of revenue and profitability from the IT security attack that it came under last month.Stating that a ransomware group has claimed responsibility for the incident, the…

The U.S. Food and Drug Administration (U.S. FDA) has approved Granules India’s abbreviated new drug application for Gabapentin Tablets USP, 600 mg and 800 mg.The approved product is bioequivalent to Neurontin Tablets, 600 mg and 800 mg, of…

Stocks to Watch on Monday.Stocks to watch: Shares of firms like IndiGo, SpiceJet, IOC, Paytm, Vodafone Idea, Granules India, and others will be in focus in Monday's trade.The Nifty futures contract traded on the Singapore Exchange indicates…

Drugmaker Granules India on Tuesday reported consolidated net profit increased 23% for December quarter to ₹124.32 crore on the back of higher paracetamol API offtake. Total income increased almost 15% to ₹1,147.07 crore. However, both the…

Granules India CMD Krishna Prasad Chigurupati (right) with Greenko Group founder, president and JMD Mahesh Kolli. Photo: Special Arrangement Drugmaker Granules plans to set up a large scale manufacturing facility for raw materials in…

The company is proposing to buyback up to 62.50 lakh shares (face value of ₹1 each) at a price of ₹400 apiece The company is proposing to buyback up to 62.50 lakh shares (face value of ₹1 each) at a price of ₹400 apiece The ₹250-crore…

Tiny ceramic ‘needles’ may be a new way to tackle back pain. The granules, smaller than a human hair, are implanted in the back instead of using bone grafts to help weld bones together to reduce pain and improve function.Over a few weeks,…

LMU scientists have shown that small aggregates function as temporary RNA repositories, which are regulated by neural activity. Cells constantly have to adapt the level of activity of certain genes to specific requirements. This applies…

Granules India consolidated net profit declined 13% year-on-year to almost ₹111 crore for the quarter ended March even as revenue from operations of the drugmaker at ₹1,030 crore was 29% more from the year earlier period.Adverse business…

Drugmaker Granules India reported consolidated net profit declined 31% to ₹101 crore for the December quarter on the back of increase in freight cost and lower gross margins. The lower net profit, compared with ₹147 crore in the year…